A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-to-Severe Plaque Psoriasis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512496-12-00

Acronym

TAK-279-PsO-3003

Enrollment

839

Registered

2025-01-16

Start date

2025-04-01

Completion date

Unknown

Last updated

2025-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate to Severe Plaque Psoriasis

Brief summary

Incidence of treatment-emergent adverses events (TEAEs), Incidence of serious adverse events (SAEs)

Detailed description

Over the duration of the study: ≥75% improvement in Psoriasis Area and Severity Index (PASI-75), Over the duration of the study: Static Physician Global Assessment (sPGA) of clear (0) or almost clear (1) with a ≥2-point decrease from baseline

Interventions

DRUGZASOCITINIB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence of treatment-emergent adverses events (TEAEs), Incidence of serious adverse events (SAEs)	—

Secondary

Measure	Time frame
Over the duration of the study: ≥75% improvement in Psoriasis Area and Severity Index (PASI-75), Over the duration of the study: Static Physician Global Assessment (sPGA) of clear (0) or almost clear (1) with a ≥2-point decrease from baseline	—

Countries

Bulgaria, Czechia, France, Germany, Hungary, Italy, Latvia, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026